ACMG Panel - Dante Labs

ACMG Panel

Regular price €49.00 EUR
/

Please note that these reports are recommended only for Whole Genome Test with 30X and up coverage

 

The Dante Labs 59 Gene Actionable Disorders Panel analyzes the 59 genes identified as medically actionable by the American College of Medical Genetics and Genomics (ACMG; Kalia et al., 2017).

These genes are medically actionable, with clinical management guidelines established for their associated conditions.

 

List of diseases screened:

  • Familial adenomatous polyposis (FAP)
  • Hereditary breast and ovarian cancer (HBOC)
  • Li-Fraumeni syndrome (LFS)
  • Peutz-Jeghers syndrome (PJS)
  • Lynch syndrome – also known as hereditary non-polyposis colorectal cancer (HNPCC)
  • MUTYH-associated polyposis (MAP)
  • Von Hippel-Lindau syndrome (VHL)
  • Multiple endocrine neoplasia type 1 (MEN1)
  • Multiple endocrine neoplasia type 2 (MEN2)
  • Familial medullary thyroid cancer
  • PTEN hamartoma tumor syndrome
  • Retinoblastoma
  • Hereditary paraganglioma-pheochromocytoma syndrome (PGL/PCC)
  • Tuberous sclerosis complex (TSC)
  • WT1-related Wilms tumor
  • Neurofibromatosis type 2 (NF2)
  • Juvenile polyposis syndrome (JPS)
  • Marfan syndrome
  • Loeys-Dietz syndrome (LDS)
  • Thoracic aortic aneurysms and/or dissections (TAAD)
  • Ehlers-Danlos syndrome, vascular type
  • Hypertrophic cardiomyopathy
  • Dilated cardiomyopathy
  • Catecholaminergic polymorphic ventricular tachycardia (CPVT)
  • Arrhythmogenic right ventricular cardiomyopathy (ARVC)
  • Romano-Ward long-QT syndrome
  • Brugada syndrome (BrS)
  • Familial hypercholesterolemia (FH)
  • Wilson disease
  • Malignant hyperthermia susceptibility (MHS)
  • Ornithine transcarbamylase (OTC) deficiency



List of genes:

APC,MYH11,ACTA2,TMEM43,DSP,PKP2,DSG2,DSC2,BRCA1,BRCA2,SCN5A,
RYR2,LMNA,MYBPC3,COL3A1,GLA,APOB,LDLR,MYH7,TPM1,MYBPC3,
PRKAG2,TNNI3,MYL3,MYL2,ACTC1,RET,PCSK9,BMPR1A,SMAD4,TNNT2,
TP53,TGFBR1,TGFBR2,TGFBR1,TGFBR2,SMAD3,KCNQ1,KCNH2,SCN5A,
MLH1,MSH2,MSH6,PMS2,PMS2,RYR1,CACNA1S,FBN1,TGFBR1,MEN1,
RET,,MUTYH,NF2,OTC,SDHD,SDHAF2,SDHC,SDHB,STK11,MUTYH,PTEN,
RB1,TSC1,TSC2,VHL,WT1,ATP7B.

We use a cutting-edge form of technology that not even the most advanced hospitals can provide and that allows us to sequenced your entire DNA with unparalleled precision, instead of focusing on only small parts of the DNA. 
Our Sequencing Center is located in L'Aquila, Italy, and with its 900 square-meter fully dedicated to Whole Genome Sequencing is considered Europe's largest private NGS laboratory. 

We perform all our analysis internally and thanks to our high-throughput next generation sequencing (NGS) equipment we guarantee superior quality.

Your sample and data will stay in the European Union (also if you are a US resident) and is protected by the EU General Data Protection Regulation (GDPR). Our technology offers data protection improvements not required by law but considered best practices in the industry.